The board of directors of the Company (the “Board”) is pleased to announce that the Group has submitted the pre-application for clinical trials for haemophilus influenzae type b (Hib) conjugate vaccine on March 27, 2024, and the pre-application for clinical trials for absorbed tetanus vaccine on February 9, 2024. The research and development of these two vaccines is in line with the Company’s strategic layout in product research and development, is an important step to realize the Company’s research and development of multidisease and multivalent products, and will further improve the Company’s product pipelines.

Invasive diseases caused by Hib may affect various organs. Common invasive diseases include meningitis, pneumonia, epiglottitis, sepsis, arthritis and cellulitis, and less frequent types of diseases include osteomyelitis, pericarditis, otitis media and acute bronchitis. In addition, the Group is actively promoting the research and development of diphtheria, tetanus and acellular pertussis and haemophilus influenzae type b (DTP-Hib) combination vaccine (hereinafter referred as the “Multidisease Vaccine”), and expects to successively submit clinical trial applications for the Multidisease Vaccine and its component vaccines since 2024. The Multidisease Vaccine is used to prevent invasive infections caused by pertussis, diphtheria, tetanus and haemophilus influenzae type b, and has the advantages such as reducing the number of vaccinations for infants and young children and enhancing the vaccination compliance of parents, infants and young children. The Multidisease Vaccine is the development trend of the industry, which provides strong support for the strengthening of the Company’s core competitiveness, enhancement of the Company’s market position, and the Company’s sustainable and steady development.